SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

IPCA Laboratories declines on receiving Import Alert from US Drug Regulator

26 Mar 2015 Evaluate

Ipca Laboratories is currently trading at Rs. 653.20, down by 11.45 points or 1.72% from its previous closing of Rs. 664.65 on the BSE.

The scrip opened at Rs. 660.00 and has touched a high and low of Rs. 673.90 and Rs. 650.05 respectively. So far 160227 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 899.30 on 30-Jun-2014 and a 52 week low of Rs. 591.25 on 09-Feb-2015.

Last one week high and low of the scrip stood at Rs. 798.00 and Rs. 650.05 respectively. The current market cap of the company is Rs. 8256.58 crore.

The promoters holding in the company stood at 45.89% while Institutions and Non-Institutions held 34.72% and 19.38% respectively.

IPCA Laboratories has got import alert from US Food and Drug Administration (USFDA) for two of its manufacturing plants. According to USFDA, IPCA Labs' unit in Pithampura (MP) and Piparia (Silvassa) have failed to meet GMP. 

This is the third import alert for the company. Earlier in January this year, US regulator had banned imports from a Madhya Pradesh manufacturing plant of Ipca, citing violations of standard production practices.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.

Ipca Laboratories Share Price

1554.85 10.90 (0.71%)
06-May-2026 10:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1831.80
Dr. Reddys Lab 1292.00
Cipla 1347.70
Zydus Lifesciences 925.90
Lupin 2400.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×